Andere Sprachen GT Biopharma, Inc.

Aktien

A402U5

US36254L3087

GTBP

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 17.05.2024			Vorbörslich 15:06:37
3,12 ^USD	-4,59 %		7,36	+135,90 %

13:52	Top Premarket Gainers	MT
26.03.	GT Biopharma, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Top Premarket Gainers	13:52
GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update	15.05.
Caterpillar deja París, el cacao está menos caliente	30.04.
Le bric-à-brac de Zonebourse : Caterpillar quitte Paris, le cacao est moins chaud	30.04.
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26.03.
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results	26.03.
GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall	01.02.
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split	01.02.
LEADING PROXY ADVISORY FIRMS, ISS AND GLASS LEWIS, RECOMMEND GT BIOPHARMA STOCKHOLDERS VOTE 'FOR' ALL PROPOSED ITEMS AT THE UPCOMING SPECIAL MEETING OF STOCKHOLDERS	07.12.
Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders	06.12.
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia	04.12.
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia	04.12.
GT BIOPHARMA PRESENTED POSITIVE PRECLINICAL DATA FOR GTB-5550, A NOVEL TRIKE MOLECULE FOR TARGETED PROSTATE CANCER TREATMENT DURING THE SOCIETY FOR IMMUNOTHERAPY OF CANCER 2023 ANNUAL MEETING	07.11.
GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting	06.11.
GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer 2023 Annual Meeting	06.11.
GT Biopharma Reports Third Quarter 2023 Financial Results	01.11.
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	01.11.
GT Biopharma : Failure to Satisfy Listing Rule - Form 8-K	23.08.23
GT Biopharma Reports Second Quarter 2023 Financial Results	07.08.23
GT Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07.08.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen GT Biopharma, Inc.

Aktien

A402U5

US36254L3087

GTBP

Andere Sprachen

Filter